Memorial Sloan Kettering Cancer Center
|Memorial Sloan Kettering Cancer Center|
|Location||Manhattan, New York City, US, United States|
|Affiliated university||Weill Cornell Graduate School of Medical Sciences|
|Emergency department||Urgent care center|
|Founded||1884 (as New York Cancer Hospital)|
|Lists||Hospitals in the United States|
|Other links||Hospitals in New York|
Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a cancer treatment and research institution in New York City, founded in 1884 as the New York Cancer Hospital. MSKCC is the largest and oldest private cancer center in the world, and is one of 47 National Cancer Institute-designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue, between 67th and 68th Streets, in Manhattan.
New York Cancer Hospital (1884–1934)
Memorial Hospital was founded on the Upper West Side of Manhattan in 1884 as the New York Cancer Hospital by a group that included John Jacob Astor III and his wife Charlotte. The hospital appointed William B. Coley as an attending surgeon, who pioneered an early form of immunotherapy to eradicate tumors. Rose Hawthorne, daughter of author Nathaniel Hawthorne, trained there in the summer of 1896 before founding her own order, Dominican Sisters of Hawthorne. In 1899, the hospital was renamed General Memorial Hospital for the Treatment of Cancer and Allied Diseases.
Around 1910 James Ewing, a professor at Cornell University's medical college, established a collaboration with Memorial Hospital with the help and funding of industrialist and philanthropist James Douglas, who gave $100,000 to endow twenty beds for clinical research, equipment for working with radium, and a clinical laboratory for that purpose. Douglas' enthusiasm and funding for development of radiation therapy for cancer inspired Ewing to become one of the pioneers in developing this treatment. Ewing soon took over effective leadership of clinical and laboratory research at Memorial. In 1916 the hospital was renamed again, dropping "General" to become known simply as Memorial Hospital. The first fellowship training program in the US was created at Memorial in 1927, funded by the Rockefellers. In 1931 the then-most-powerful 900k-volt X-ray tube was put into use in radiation-based cancer treatment at Memorial; the tube had been built by General Electric over several years. In 1931 Ewing was formally appointed president of the hospital, a role he had effectively played until then, and was featured on the cover of Time Magazine as "Cancer Man Ewing"; the accompanying article described his role as one of the most important cancer doctors of his era. He worked at the Memorial until his retirement, in 1939. Under his leadership, Memorial became a model for other cancer centers in the United States, combining patient care with clinical and laboratory research, and it was said of him that "the relationship of Ewing to the Memorial Hospital can best be expressed in the words of Emerson, 'Every institution is but the lengthening shadow of some man.' Dr. Ewing is the Memorial Hospital".
Memorial Hospital and the Sloan Kettering Institute (1934–1980)
In 1934, John D. Rockefeller, Jr. donated land on York Avenue for a new location. Two years later, he granted Memorial Hospital $3,000,000 and the hospital began their move across town. Memorial Hospital officially reopened at the new location in 1939. In 1945, the chairman of General Motors, Alfred P. Sloan, donated $4,000,000 to create the Sloan-Kettering Institute for Cancer Research through his Sloan Foundation, and Charles F. Kettering, GM's vice president and director of research, personally agreed to oversee the organization of a cancer research program based on industrial techniques. The originally independent research institute was built adjacent to Memorial Hospital.
In 1948 Cornelius P. Rhoads became the director of Memorial. Rhoads had run chemical weapons programs for the US army in World War II, and had been involved in the work that led to the discovery that nitrogen mustards could potentially be used as cancer drugs.:91–92 He fostered a collaboration between Joseph H. Burchenal, a clinician at Memorial and Gertrude B. Elion and George H. Hitchings at Burroughs Wellcome, who had discovered 6 MP; the collaboration led to the development and eventual wide use of this cancer drug.:91–92
From the mid-1950s to the mid-1960s Chester M. Southam conducted pioneering clinical research on virotherapy and cancer immunotherapy at MSK; however he conducted his research on people without their informed consent. He did this to patients under his care or others' care, and to prisoners. In 1963 some doctors objected to the lack of consent in his experiments and reported him to the Regents of the University of the State of New York which found him guilty of fraud, deceit, and unprofessional conduct, and in the end he was placed on probation for a year. Southam's research experiments and the case at the Regents were followed in the New York Times.
In 1960, Memorial Sloan Kettering Cancer Center was formed as a new corporation to coordinate the two institutions; John Heller, the former director of the National Cancer Institute was named its president. At the end of the 1960s, as the field of pediatric oncology began seeing success in treating children with cancer, Memorial opened an outpatient pediatric day hospital, partly to deal with the growing number of cancer survivors. In the early 1970s, Burchenal and Benno Schmidt, a professional investor and trustee of MSK, were appointed to the presidential panel that initiated the U.S. federal government's War on Cancer in the early 1970s.:184 When Congress passed the National Cancer Act of 1971 as part of that effort, Memorial Sloan Kettering was designated as one of only three Comprehensive Cancer Centers nationwide. In 1977, Jimmie C. Holland established a full-time psychiatric service at MSK dedicated to helping people with cancer cope with their disease and its treatment; it was one of the first such programs and was part of the creation of the field of psycho-oncology.
Memorial Sloan Kettering Cancer Center (1980–present)
In 1980 Memorial Hospital and the Sloan-Kettering Institute formally merged into a singular entity under the Memorial Sloan Kettering Cancer Center name.
In 2000, former NIH director Harold Varmus became the director of MSK. During his tenure, he helped build new facilities, strengthened the bond between MSK's clinical and research arms, and fostered collaborations with other institutions, including Weill-Cornell Medical College and Rockefeller University.
In 2006, MSK opened the Mortimer B. Zuckerman Research Center, a 23-story building which houses more than 100 laboratories.
Craig B. Thompson, oncologist and researcher, was appointed MSK's president and CEO in 2010. The following year, MSK was rated the third most successful nonprofit in terms of FDA-approved drugs and vaccines, behind the National Institutes of Health and the University of California system. In 2012, Thompson appointed José Baselga as physician-in-chief, who directs the clinical side of MSK. That same year, a collaboration with IBM's Watson was announced with the goal of developing new tools and resources to better tailor diagnostic and treatment recommendations for patients. The director of SKI, the research arm of MSK, Joan Massagué was appointed in 2013.
MSK currently employs over 1,000 physicians and treats more than 600,000 patients with approximately 400 types of cancer annually.
Associated facilities and programs
The Memorial Sloan Kettering Bendheim Integrative Medicine Center occupies 1429 First Avenue on the corner of East 74th Street in Manhattan. The former bank was built in the 1930s by Perkins and Will as architects. It was remodeled for use by Memorial Sloan Kettering in 1997.
MSK has an extensive history of notable discoveries in cancer research. The research arm of MSK is still known as the Sloan Kettering Institute after the merger with Memorial Hospital. Memorial Hospital separately houses a number of laboratories. In 2011, a study ranked MSK third among public sector research institutes after the NIH and University of California system.
Notable cancer treatments developed at MSK include chimeric antigen receptor therapy, enzalutamide, HSP-90 inhibitors, Ipilimumab, Pralatrexate, Filgrastim, Thyrogen, aldesleukin, Zolinza, Ganite, Trisenox, clofarabine,
Research is organized into several programs within the Sloan Kettering Institute and Memorial Hospital:
- Cancer Biology & Genetics – led by Scott W. Lowe
- Cell Biology
- Chemical Biology – led by Derek Tan
- Computational and Systems Biology – led by Dana Pe'er
- Developmental Biology – led by Kathryn V. Anderson
- Immunology – led by Alexander Rudensky
- Molecular Biology – led by John Petrini
- Molecular Pharmacology – led by David A. Scheinberg
- Structural Biology – led by Nikola Pavletich
- Human Oncology and Pathogenesis – led by Charles Sawyers
A number of Collaborative Research Centers have also been established at MSK.
- Brain Tumor Center
- Center for Cancer Systems Immunology
- Center for Cell Engineering
- Center for Epigenetics Research
- Center for Experimental Therapeutics
- Center for Health Policy & Outcomes
- Center for Hematologic Malignancies
- Center for Molecular Imaging & Nanotechnology
- Center for Stem Cell Biology
- Center of Comparative Medicine & Pathology
- David M. Rubenstein Center for Pancreatic Cancer Research
- Fiona and Stanley Druckenmiller Center for Lung Cancer Research
- The Functional Genomics Initiative
- Geoffrey Beene Cancer Research Center
- Immunogenomics and Precision Oncology Platform (IPOP)
- Lucille Castori Center for Microbes, Inflammation & Cancer
- Ludwig Center for Cancer Immunotherapy
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- Metastasis and Tumor Ecosystems Center
- MSK-Cornell Center for Translation of Cancer Nanomedicine
- Parker Institute for Cancer Immunotherapy
- Survivorship, Outcomes & Risk Program
In 2004, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences was opened at Memorial Sloan Kettering Cancer Center, with the goal of furthering research by introducing students to an interactive and innovative environment. The first students graduated in 2012.
The Tri-Institutional MD–PhD Program is a partnership of MSKCC, The Rockefeller University, and Weill Cornell Graduate School of Medical Sciences, and Cornell University. The biomedical program takes advantage of the close proximity of these three institutions for collaboration on biomedical research and Cornell's MD–PhD program. The Tri-Institutional Training Program in Computational Biology and Medicine is a similar partnership.
- Craig B. Thompson
- Alexander Rudensky
- Charles Sawyers
- Joan Massagué
- Jose Baselga
- Lorenz Studer
- Paul Marks
- Jimmie C. Holland
- Scott W. Lowe
- Nikola P. Pavletich
- Mark S. Ptashne
- Murray Brennan
- Kenneth Offit
- Samuel Danishefsky
In 2015 Charity Watch rated Memorial Sloan Kettering Cancer Center an "A". Heads of the charity received $2,107,939 to $2,639,669 salary/compensation from the charity. CEO Craig B. Thompson received $2,554,085 salary/compensation from the charity.
- "Memorial Sloan Kettering Cancer Center". Forbes.
- Barbanel, Josh. "Would an Aardvark Live Here?" The New York Times, September 17, 2006. Retrieved December 31, 2009.
- "The New York Cancer Hospital: laying the corner-stone of a much-needed institution". The New York Times. May 18, 1884. Retrieved February 4, 2016. (Subscription required (. ))
- Abel, Emily K. (2013). The inevitable hour: a history of caring for dying patients in America. Baltimore, Md.: Johns Hopkins University Press. pp. 66–67. ISBN 978-1421409191. OCLC 808769549.
- Coley to Cure:The Story of the Cancer Research Institute. Cancer Research Institute. 2014. pp. 12–13. Retrieved February 4, 2016.
- Smith, Fran; Himmel, Shiela (2013). Changing the Way We Die: Compassionate End of Life Care and The Hospice Movement. Berkeley, California: Cleis Press. p. 23. ISBN 9781936740604. OCLC 839388370.
- "SESSION OF THE SENATE.; Bills Passed and Introduced and Routine Business Transacted". The New York Times. February 16, 1899. Retrieved February 27, 2016. (Subscription required (. ))
- Murphy, James B. (1951). "James Ewing — 1866–1943" (PDF). Biographical Memoirs. Washington, D.C.: National Academy of Sciences.
- Memorial Hospital for the Treatment of Cancer and Allied Diseases Thirty First Annual Report for the Year 1915 (Report). p. 19.
- Wilkins, Sam A. Jr. (February 25, 1970). "James Ewing Society, 1940-1969: Presidential Address" (PDF). pp. 321–323. PMID 4905156.
- "900,000-VOLT TUBE TO COMBAT CANCER: Largest X-Ray Device of Kind Being Built by General Electric for Hospital Here". The New York Times. March 1, 1931. Retrieved February 4, 2016.
- Time Magazine Cover, January 12, 1931
- Cancer Crusade. January 12, 1931. Time Magazine 17(2):26
- Brand, RA (Mar 2012). "Biographical sketch: James Stephen Ewing, MD (1844-1943)". Clin Orthop Relat Res. 470 (3): 639–41. doi:10.1007/s11999-011-2234-y. PMC . PMID 22207564.
- "Rockefeller Gives Block to Institute". The New York Times. December 28, 1934. Retrieved February 4, 2016.
- "Rockefeller Provides $3,000,000 to Build Cancer Hospital Here". The New York Times. April 28, 1936. Retrieved February 4, 2016.
- "THE MEMORIAL HOSPITAL". The New York Times. June 16, 1939. Retrieved February 27, 2016.
- Memorial Sloan Kettering Cancer Center, History & Milestones. Memorial Sloan Kettering Cancer Center website..
- "Sloan, Kettering to Combat Cancer; Studying Sketch of Proposed Cancer Research Institute". The New York Times. August 8, 1945. p. 1 (cont'd p. 40).
- Mukherjee, Siddhartha (2010). The Emperor of All Maladies: A Biography of Cancer. New York. ISBN 978-1439170915.
- Bouton, Katherine (January 29, 1989). "The Nobel Pair". The New York Times.
- Skloot, Rebecca (2010). The Immortal Life of Henrietta Lacks. New York: Crown/Archetype. pp. 127–135. ISBN 9780307589385.
- Mulford, R.D. (1967). "Experimentation on Human Beings". Stanford Law Review. 20 (1): 99–117. doi:10.2307/1227417.
- "14 Convicts Injected With Live Cancer Cells". The New York Times. June 15, 1956.
- Johnston, Richard J.H. (April 15, 1957). "Cancer Defenses Found to Differ; Tests Indicate Victims Lack Some Mechanisms That Well Human Being Has Cancer Recurred Deficiency Is Noted Warning by Southam". The New York Times.
- Osmundsen, John A. (January 26, 1964). "Many Scientific Experts Condemn Ethics of Cancer Injection". The New York Times.
- Plumb, Robert K. (March 22, 1964). "Scientists Split on Cancer Tests". The New York Times.
- "Ruling is Upset on Cancer Test". The New York Times. July 8, 1964.
- "U.S. Aide to Head Cancer Center: Dr. John R. Heller, Cured of Disease, to Assume New Sloan-Kettering Post". The New York Times. April 19, 1960. Retrieved February 4, 2016.
- Johnson, Rudy (December 3, 1972). "Parents Are on Team at Memorial's Day Hospital for Children With Cancer". The New York Times.
- Marks, Paul; Sterngold, James (2014). On the Cancer Frontier: One Man, One Disease, and a Medical Revolution. PublicAffairs. p. 91. ISBN 1610392523.
- Memorial Sloan-Kettering Cancer Center Annual Report, 1977 (Report). p. 22.
- Rosenthal, Elizabeth (July 20, 1997). "Scientist at Work: Jimmie Holland; Listening to the Emotional Needs of Cancer Patients". The New York Times. Retrieved March 22, 2016.
- "The Harold Varmus Papers: Memorial Sloan Kettering Cancer Center, 2000-2010, and National Cancer Institute, 2010-2015". profiles.nlm.nih.gov. Retrieved April 22, 2016.
- "Sloan Kettering Institute: About SKI". Memorial Sloan Kettering Cancer Center. Retrieved December 4, 2017.
- "Craig Thompson Named President of Memorial Sloan-Kettering Cancer Center". Memorial Sloan Kettering Cancer Center. August 10, 2010. Retrieved January 10, 2013.
- Stevens, AJ; Jensen, JJ; Wyller, K; Kilgore, PC; Chatterjee, S; Rohrbaugh, ML (February 10, 2011). "The role of public-sector research in the discovery of drugs and vaccines". The New England Journal of Medicine. 364 (6): 535–41. doi:10.1056/NEJMsa1008268. PMID 21306239.
- "Center names physician-in-chief". HemOnc Today. November 10, 2012.
- Memorial Sloan-Kettering Cancer Center Annual Report, 2013. p. 5.
- Barajas, Carlos (November 26, 2013). "El español Joan Massagué, al frente del Sloan-Kettering de Nueva York". El Mundo.
- "History & Milestones". Memorial Sloan Kettering Cancer Center. Retrieved December 4, 2017.
- Norval White; Elliot Willensky; Fran Leadon. AIA Guide to New York City. Retrieved January 10, 2013.
- "Memorial Hospital Research". Memorial Sloan Kettering Cancer Center. Retrieved December 4, 2017.
- Stevens, Ashley J.; Jensen, Jonathan J.; Wyller, Katrine; Kilgore, Patrick C.; Chatterjee, Sabarni; Rohrbaugh, Mark L. (February 10, 2011). "The Role of Public-Sector Research in the Discovery of Drugs and Vaccines". New England Journal of Medicine. 364 (6): 535–541. doi:10.1056/NEJMsa1008268. PMID 21306239. Retrieved December 4, 2017 – via Taylor and Francis+NEJM.
- "Office of Technology Development: Success Stories". Memorial Sloan Kettering Cancer Center. Retrieved December 4, 2017.
- "Research Programs & Centers". Memorial Sloan Kettering Cancer Center. Retrieved December 4, 2017.
- Memorial Sloan-Kettering Cancer Center Annual Report, 2005. p. 3.
- "First Four Students Receive Doctoral Degrees from Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences". Memorial Sloan Kettering Cancer Center. Retrieved December 4, 2017.
- "Charity Ratings". charitywatch.org. Retrieved April 5, 2016.
- "U.S. News & World Report Releases 2015–16 Best Hospitals". US News & World Report. July 21, 2015. Retrieved April 5, 2016.
- "Hospital Rankings by Specialty: Cancer". U.S. News & World Report. Archived from the original on August 24, 2017.
- Official website
- Gerstner Sloan–Kettering Graduate School of Biomedical Sciences
- Weill Cornell Graduate School of Medical Sciences